Welcome to Multibagg AI
Log in to access personalized features
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Discovery themes featuring this stockDiscover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Epigral Ltd (EPIGRAL) is currently trading at 880.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Epigral Limited, formerly Meghmani Finechem Limited, is a prominent player in India's chlor alkali industry, involved in manufacturing chlor alkali products and derivatives, along with trading agrochemicals. The company has recently finalized capex plans aiming to double the capacity of its CPVC and epichlorohydrin plants, hinting at a robust strategic expansion. Revenue increased modestly by 2% in Q3 FY26, driven by volume growth despite challenging market conditions due to geopolitical uncertainties and a prolonged monsoon season. Epigral reported an EBITDA margin contraction to 17% due to lower product realizations and rising raw material costs, although sustained 9-month margins were at 22%. Forward integration efforts continue with commission of India's first Chlorotoluenes Value Chain Facility and plans for an upcoming pilot plant, reflecting a focus on expanding vertically and improving manufacturing capabilities.
Over the past 52 weeks, Epigral Ltd has traded between a low of ₹822.05 and a high of ₹2,114.30. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Epigral Ltd has a market capitalization of approximately 3,819.95. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Epigral Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 11.23 and operates in the Chemicals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 3,819.95 Cr, Epigral Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Epigral Ltd operates in the Chemicals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Epigral Ltd is 11.23. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
252.60 | 4,076 Cr | -13.98 | 138.67 | 0.00 | -11.18 | -1.13 | -4.46 | |
1477.00 | 3,938 Cr | 197.46 | 4.92 | 0.07 | 4.11 | 5.72 | 0.86 | |
882.00 | 3,820 Cr | 11.26 | 1.82 | 0.68 | 19.15 | 19.53 | 10.44 | |
1014.00 | 3,327 Cr | 22.92 | 1.77 | 1.07 | 7.75 | 10.38 | 6.21 | |
484.40 | 3,265 Cr | 23.62 | 3.26 | 0.06 | 13.84 | 15.78 | 7.54 | |
444.50 | 3,258 Cr | -379.91 | 0.58 | 3.56 | 0.00 | 0.84 | -0.10 | |
62.56 | 2,837 Cr | 20.25 | 2.84 | 0.80 | 15.14 | 20.01 | 10.56 |
Bearish
3
Neutral
6
Bullish
5
Bearish
27
Neutral
6
Bullish
13
Bearish
24
Neutral
0
Bullish
8
Epigral Limited, formerly Meghmani Finechem Limited, is a prominent player in India's chlor alkali industry, involved in manufacturing chlor alkali products and derivatives, along with trading agrochemicals.
The company has recently finalized capex plans aiming to double the capacity of its CPVC and epichlorohydrin plants, hinting at a robust strategic expansion.
Revenue increased modestly by 2% in Q3 FY26, driven by volume growth despite challenging market conditions due to geopolitical uncertainties and a prolonged monsoon season.
Epigral reported an EBITDA margin contraction to 17% due to lower product realizations and rising raw material costs, although sustained 9-month margins were at 22%.
Forward integration efforts continue with commission of India's first Chlorotoluenes Value Chain Facility and plans for an upcoming pilot plant, reflecting a focus on expanding vertically and improving manufacturing capabilities.
Chemicals
Chemicals - Speciality - Large
3,820 Cr
High Risk
11.2
42.8
1.0
1.8
2,114.30
822.05
Sales CAGR
Profit CAGR
ROE
ROCE
